Trazimera Indications/Uses

Breast cancer: Metastatic breast cancer: TRAZIMERA is indicated for the treatment of patients with metastatic breast cancer (MBC) who have tumors that overexpress human epidermal growth factor receptor 2 (HER2): as monotherapy for the treatment of those patients who have received one or more chemotherapy regimens for their metastatic disease; in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease; in combination with an aromatase inhibitor for the treatment of patients with hormone-receptor positive MBC.
Early breast cancer: TRAZIMERA is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC): following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable) (see Pharmacology: Pharmacodynamics under Actions); following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxel; in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin; in combination with neoadjuvant chemotherapy followed by adjuvant TRAZIMERA, for locally advanced (including inflammatory) breast cancer or tumours >2 cm in diameter (see Precautions and Pharmacology: Pharmacodynamics under Actions).
Advanced gastric cancer: TRAZIMERA in combination with capecitabine or intravenous 5-fluorouracil and a platinum agent is indicated for the treatment of patients with HER2 positive advanced adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.